← brief for 2026-09-03 · Slowing decline

Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy

Paper C Peer reviewed Observational

Key takeaways

Telitacicept is a drug being tested for membranous nephropathy, a disease where the kidney's filters leak protein into the urine. This report covers people whose disease did not get better after rituximab, the usual next drug to try. It describes how much the leaking dropped and what side effects came up. There was no comparison group, so this shows a link between the drug and improvement, not proof that the drug caused it.

Who did this work

Xiaomiao He · Yiqi Huang · Zhongjie Qu · Peng Cheng · Yinghui Xu · Yiming Jin

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-03
https://doi.org/10.1007/s11255-026-05376-x